Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expectations regarding therapy, which will need to be effective in a shorter period of time. New technologies for the treatment of BPH are anticipated. Already, robot-operated vaporisation of the prostate is being undertaken. With regard to medical therapy, more selective and hence, more effective drugs are under development. With the identi®cation of new a 1 -adrenoceptor subtypes, a-blocker therapy should target the prostate more accurately. Gene-based therapies will have an important role in the future. It is envisaged that technology will exist whereby defective genes can be replaced and gene expression controlled to overcome the disease process. Through pharmacogenomics, drugs will be tailored to the individual, which will, in turn, result in more economical use of medical therapy. Similarly, the development of nanotechnology will allow sitespeci®c delivery of drugs. Together, these advances will make the treatment of BPH even more effective in the new millennium.
Prevalence of BPH
Benign prostatic hyperplasia (BPH) is an age-related disease that is highly prevalent, with approximately 90% of men aged over 80 y having histological evidence of the disorder. 1 Community-based studies have evaluated the prevalence of symptomatic BPH or lower urinary tract symptoms (LUTS) by age in several European countries, 2 ± 5 the US 6 and Japan. 7 Results show that one in four men aged 50 y have LUTS, increasing to one in two men aged 65 y.
The world population continues to grow by approximately 80 million each year, the equivalent to the current population of Germany, and it is expected to double by the year 2060, reaching a total of 10 billion people (Table  1) . 8 This is partly explained by the fact that the world population is ageing, with people enjoying a greater life expectancy. It is currently estimated that each month the population aged b 65 y increases by 800 000. 8 In addition, a signi®cant percentage of men, particularly those living in developed countries, will reach a century. As nearly 50% of men b 65 y are at risk of LUTS suggestive of BPH, with the ageing population, LUTS is set to become even more prevalent in the future. The projected increase in the world male population aged b 65 y, leads to the assumption that, by the year 2010, 115 million men will have LUTS ( Table 2) . 8 This means that in just 50 years time, there will be three times as many men suffering from BPH.
The changing population
With the technological developments that are ongoing, patients will become better informed about their disease conditions. The Internet as a source of information will continue to evolve and patients will have increasing access to comprehensive information on their condition. In addition, it is anticipated that patients will have more time to expand their knowledge, particularly of diseases that affect them directly. With direct access to electronic information concerning the diagnosis and treatment options for BPH, more and more patients will be able to make their own treatment decisions and challenge their doctor's opinion. With regard to the practitioner, patients will demand information on the risks of a particular treatment, as well as its advantages and disadvantages.
Data on success rates of speci®c treatments will be requested, and ultimately, patients will expect individualised evidence-based solutions to their problems.
As patients with BPH will be living longer, quality of life will become a major issue. LUTS will not be tolerated for these increasing lengths of time Ð patients will expect such problems to be dealt with quickly and effectively. Equally, the complications of treatment will not be tolerated, particularly with regard to sexual function, which patients will expect to be sustained into later years. As age is a risk factor for complications of BPH, 9 clearly this ageing population will be at increased risk, although to what extent is not yet known.
From the doctor's perspective, he/she will need to keep up with the developing technologies and continuous medical education will be needed even more than in the present day. Moves are under way in Europe towards this end, with re-certi®cation of specialists being considered. This process is already established in the US and it is highly likely that Europe will follow (The European Board of Urology is actively working in collaboration with the European Association of Urology to regulate Continuing Medical Education in urology).
The question remains as to what can society afford to pay for the treatment of BPH in the future. This will certainly affect the treatment options that can be offered to patients. Undoubtedly, treatments will need to be highly effective with minimal side effects.
New treatment strategies Minimally invasive therapies
The continuing advances in computing, cybernetics and medical engineering and the fact that the prevalence of BPH is increasing clearly predicts progress in the treatment of BPH in the area of minimally invasive procedures. Three factors will be essential for any new invasive treatment: ef®cacy, low morbidity and cost effectiveness, and these will have to be balanced against each other. An example of this can be seen with the existing surgical procedures: transrectal resection of the prostate (TURP) and open prostatectomy (Figure 1 ). It can be seen that although TURP is slightly less effective and associated with a higher reoperation rate than the open procedure, it is associated with a lower morbidity and lower costs. 10, 11 New techniques already under development at University College London, UK, include a computer-controlled transrectal ultrasound-guided robot system that uses vaporisation of the prostate to relieve obstruction. The robot uses a counterbalanced mounting frame to hold and manipulate the resectoscope. An on-line transrectal ultrasound imaging system monitors the procedure by constructing a 3-D prostate model and there is an appropriate surgeon ± computer interface. 12 To date, 43 patients have undergone this procedure and only three failures have been reported due to technical problems.
Medical therapy
An increased understanding of LUTS suggestive of BPH is expected in the future. This will allow the development of selective drugs which are more effective. New mechanistic approaches are also envisaged, some of which are already under way (Table 3) .
Molecular and pharmacological studies led to the subdivision of a 1 -adrenoceptors into three a 1 -subtypes (a 1A , a 1B and a 1D ). 13 An alternative subdivision in a 1H (high Figure 1 Comparative cost, effectiveness and morbidity associated with invasive therapies for BPH. TURP transurethral resection of the prostate.
af®nity for prazosin) and a 1L (low af®nity for prazosin), which has yet to be supported by molecular biological evidence, has also been proposed. 14, 15 The de®nition of a 1 -adrenoceptor subtypes fuelled the hypothesis that a selective a 1A -subtype antagonist may lead, through a selective blockade of a 1A -adrenoceptors in the lower urinary tract, to an improved therapy of BPH. This hypothesis awaits the support of clinical data. The possibility remains that further a 1 -adrenoceptor subtypes may be cloned. If new subtypes speci®c for tissues involved in bladder outlet resistance are found, this should provide the basis for the understanding of the mechanism underlying the uroselective pro®le of existing a 1 -blockers, as well as for the rational design of new drugs acting preferentially on the disease tissue.
BPH is characterized by an imbalance between proliferation and apoptosis of stromal and epithelial cells, resulting in an abnormal growth of the gland. Hence, activation of the apoptotic pathways within the prostate could potentially be an effective mechanism for the longterm management of BPH. a 1 -Blockers, such as terazosin and doxazosin, have been shown to increase apoptosis in both epithelial and smooth muscle cells taken from men with BPH treated for 3 ± 36 months and this is independent of their capacity to antagonize a 1 -adrenoceptors. 16 Endothelin-1 is an abundant prostate secretory protein that, in its biologically active form, elicits prostatic smooth muscle contraction. The role of endothelins in prostate smooth muscle cell growth has been examined in in vitro studies. In one study, endothelin-1 and endothelin-3 induced a concentration-dependent increase in DNA synthesis and also promoted cell growth. 17 It was suggested that these effects may contribute to smooth muscle hyperplasia associated with BPH. A number of endothelin receptor antagonists are currently under development. 18, 19 Many growth factors have a role in the development of BPH and both upregulation and antagonism of growth factors are attractive therapeutic options. For example, transforming growth factor beta (TGF-b) signalling has been implicated in apoptotic cell death and in the normal prostate, it acts as a predominantly negative growth factor regulator. 20 Therapeutic outcome could be enhanced in various ways, including matching patients with particular cell type overgrowth for treatment with a growth factor antagonist speci®c for that cell type.
The therapeutic potential of monoclonal antibodies, genetically engineered proteins designed to target disease sites in the body, is now currently accepted. Developments in this technology have been made in the areas of in¯ammation, autoimmune disorders and cancer.
Advances in phage display and more recently in transgenic technology 21 have allowed the generation of fully human monoclonal antibodies, which are likely to achieve even greater clinical success as they further reduce the risk of immune reactions. The potential of this approach in the treatment of BPH requires the characterisation of speci®c antigenic targets. If this goal is achieved, drugs directed towards these potential targets may provide improved therapeutic margin as the result of high speci®city for the disease tissue.
Gene-based medicine
Therapies for BPH will inevitable become more focused, with the target becoming the prostate cells themselves as opposed to the whole gland. More speci®cally, genetics is considered by many to be the ®eld in which the next revolution in medicine will occur. The Human Genome project, which is an effort to map and sequence the entire human genome, is expected to ®nish in 2000, ahead of schedule. Already, the information gathered is leading to better diagnostic and therapeutic approaches to clinical medicine.
The ultimate goal of genetic medicine is to learn how to prevent disease or to treat it with gene therapy or a drug developed speci®cally for the underlying defect. In terms of prostatic diseases, it is expected that the genetic cascade that leads to the development of BPH and prostate cancer will probably be elucidated by the year 2005. The ®rst step in molecular biology that can be applied to the treatment of BPH will be in diagnosis, through the screening of patients predisposed to the disease. The second step will be to devise speci®c therapeutic interventions based on the genetic pathway. A number of different strategies are envisaged, including:
Insertion of normal genes to compensate for missing or damaged genes using viral or arti®cially engineered vectors, Regulation of the mechanisms by which genes are activated or shut off, Targeting mRNA to control gene expression, Mitigating or neutralising the effects of missing or abnormal proteins.
Pharmacogenomics
It has been noted that some drugs work better in certain individuals than others, and some drugs may in fact be toxic to particular individuals. 22, 23 The ®eld of pharmacogenomics addresses the issues of genetic variability amongst individuals and its effects on drug response. The aim of pharmacogenomics is to develop new diagnostic procedures and therapeutic products that enable drugs to be prescribed selectively to patients for whom it will be safe and effective. Three recent developments are responsible for the increased interest in pharmacogenomics. The ®rst is the recognition that the systematic discovery of genetic variance can provide important opportunities for developing new therapeutic and diagnostic products from genomics. The second is the capability to identify genetic variation in the human population along the same timelines as drug GnRH gonadotrophin-releasing hormone development. Thirdly, the emergence of managed care as an economic force in medicine provides an economic incentive for the use of pharmacogenomics by pharmaceutical companies and health-care providers.
The application of genomic technologies has expanded the opportunity for identifying genetic effects on drug action. Studies have begun to identify common variances in genes that control the activation, distribution, or elimination of many drugs. The result will be that drugs that are potentially toxic to the patient will be avoided, effective therapies will be prescribed sooner, and diseases will be more effectively and economically managed.
Because drug-metabolizing enzymes are an important determinant of drug disposition, safety and ef®cacy, and are known to be genetically variable, they will be an obvious target in studies to assess the origins of individuality in drug response. 24 The frequency of polymorphisms in some important drug metabolism genes has already been studied in different ethnic groups (Table 4) . 25 
Clinical application
ApoE4, an allele at the apolipoprotein E locus, is an example of a polymorphism within a disease-related gene that is predictive of drug response. This not only correlates with the risk of developing Alzheimer's disease, but also predicts poor response to cholinesterase treatment. Individuals homogenous for the ApoE4 allele respond much more poorly to tacrine than patients with other ApoE genotypes. 26 In the long term, the greatest impact of pharmacogenomics will be in diseases that are inherently variable. For example, rapid genotyping of bacteria for drug resistance will allow the physician to prescribe the correct treatment within hours rather than giving broad-spectrum antibiotics. In oncology, chemotherapy resistance-associated genetic markers in tumour cells are being sought to guide treatment choices and spare patients futile therapy with highly toxic agents. Hence, it should be possible in the near future to determine easily which BPH patients will respond best to which types of drugs without developing side effects. This will undoubtedly provide cost savings to the health-care system by increasing the effectiveness of the initially prescribed therapy, reducing the number of hospital visits, eliminating the cost of prescribing ineffective pharmaceutical products, and eliminating avoidable toxicities.
Nanotechnology
Another developing technology in disease treatment that is expected to be in clinical use in the new millennium is nanotechnology. 27 We have witnessed a trend towards progressive miniaturization of devices through the 1980s and 1990s. This trend continues today as scientists develop methods for building materials and devices by manipulating atoms directly or through chemical or biological means. The improved understanding of biochemistry and technological advancements will allow the design of molecular structures with a speci®c function. 28 This capability to produce nanodevices in conjunction with the vast knowledge of molecular biology will change our ability to interact with the cellular processes. Nanotechnology will probably also be applied to the design and production of speci®c vectors, which will recognise prostatic tissue.
Colloidal particles in the nanometre size range (`1 mm diameter) can be engineered to provide opportunities for site-speci®c delivery of drugs after injection into the general circulation or lymphatic system. Targets include various tissues, such as the liver, endothelial cells, sites of in¯ammation, lymph nodes and prostatic cells. The size and surface of the particle are crucial factors in targeting, and the attachment of cell-speci®c ligands can lead to increased selectivity.
The established fate of nanoparticles following intravenous administration indicates the diverse physicochemical and biological events that need to be considered in the design of a colloidal targeting system. It has been shown that after nanoparticles are injected into the blood stream they are rapidly coated by elements of the circulation, such as plasma proteins and glycoproteins in a process known as opsonization (Figure 2 ). Normally this process would make the particle immediately recognisable by the mononuclear phagocyte system. The macrophage (Kupffer) cells of the liver play a crucial role in removing these particles. Uptake of particles by Kupffer cells represents an excellent example of passive targeting and this can be exploited to help treatment in disease conditions such as leishmaniasis and listeria, where macrophages are directly involved in the disease process. The capture of particles by macrophages has also been exploited to achieve controlled delivery of drugs to the blood circulation. However, in many situations, the Kupffer cells represent a major barrier to other sites in and beyond the vascular compartment. Particles can be disguised, however, by making their surfaces hydrophilic as well as sterically stabilised using adsorbed polymers, such as block copolymer or poloxyethylene groups. 29 There is no doubt that nanotechnology will provide the horsepower for molecular medicine, allowing us to reach the con®nes of the prostatic cells themselves and interact with the cellular processes that lead to BPH and cancer.
Conclusion
The better understanding of the pathophysiology of LUTS, including the identi®cation of new a 1 -adrenoceptor subtypes and improved patient selection will lead to the development of more ef®cacious drugs for BPH. Such drugs will have minimal side effects and will prevent the long-term complications of the disease. With the acceleration of the development of new medicines and techniques, clinicians will need to determine which patients will respond best to which treatment in order to offer patients the best medical care possible. Arti®cial intelligence in the form of computers and precise treatment guidelines will assist them in making these decisions. A progressive shift from treatment to early detection is also expected. Molecular technologies will assist in the identifying patients at risk of BPH and instituting prevention strategies. It is quite possible, that in the future, BPH will no longer exist, as predisposition to the disease will have been identi®ed and disease development prevented.
